SEC Filings
Ocular Therapeutix Adds Oculis CEO Riad Sherif — Seung Suh Hong To Leave Board
Sherif’s director awards include options on 88,000 shares and restricted stock units covering 28,000 shares.
Ocular Therapeutix (OCUL) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
Sherif’s director awards include options on 88,000 shares and restricted stock units covering 28,000 shares.
Earnings
Research costs rose as revenue fell, while the company prepares a fourth-quarter FDA application for its investigational eye implant.
SEC Filings
Sanjay Nayak told the company of his decision Wednesday; an 8-K filed Friday says he is leaving to become CEO of a privately held company.